Monday, February 16, 2026 2/16/2026

Lipoxygenase Signaling in Heart Failure Pathology

Award Number: R01HL144788
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/01/2019
PERIOD OF PERFORMANCE END DATE: 05/31/2024

Group Awards By:

View Award Description

Lipoxygenase Signaling in Heart Failure Pathology - Summary: Chronic inflammation following myocardial infarction (MI) can progress to heart failure (HF) with excess morbidity and mortality; therefore, improvement in left ventricular (LV) function and survival after MI are hard endpoints that provide the ultimate test of therapeutic efficacy. While multiple factors impact adverse cardiac remodeling and HF progression, emerging studies lend credence to the concept that aberrant lipid metabolism contributes importantly to chronic inflammation and subsequent HF. Traditionally, all lipoxygenase (LOX)-derived lipid mediators have been considered proinflammatory and detrimental. However, acute inflammation is necessary for early healing; therefore, rather than inhibition of all inflammation, the goal of therapy should be to achieve an optimal balance between inflammation-promoting and -resolving factors. Our data indicate that deletion of 12/15LOX in mice delays HF post-MI, improves infarct healing, and reduces LV dysfunction and mortality by promoting the formation of the resolving lipid mediators, cypoxins that polarize leukocytes to a reparative phenotype. These data suggest that 12/15LOX activity underlies non-resolving inflammation following MI, thereby negatively impacting LV function and mortality. Our data in mice and patients with HF suggest that an eicosanoid product of 12/15LOX-induced arachidonic acid metabolism, 12(S)- hydroxyeicosatetraenoic acid, delays leukocyte clearance in the post-MI heart, delaying inflammation resolution. Which specific myeloid-leukocyte population contributes to bioactive lipid mediator generation after MI remains unclear; our data point to a critical role for macrophages. Thus, we hypothesize that macrophage- produced 12/15LOX is a key regulator of both inflammation-triggering and -resolving pathway(s) after MI healing, and these must be balanced to alleviate the progression to HF. To test this hypothesis, we propose three aims. Aim 1: Determine if 12/15LOX deficiency reduces inflammatory mediators to control overactive inflammation in acute HF after MI (days 1 to 5), using a myeloid-specific 12/15LOX-knockout mice. Aim 2: Test whether myeloid-specific 12/15LOX deficiency limits proinflammatory and promotes proresolving mediators biosynthesis to promote effective healing after MI, and thereby delays the progression to chronic HF. We will determine the proinflammatory and proresolving mediators in the infarcted area using quantitative and imaging mass spectrometry approaches that were technologically unfeasible before, and determine the mechanism by which macrophage-specific 12/15LOX balances proinflammatory and proresolving mediators. Aim 3: Establish whether post-MI inhibition of 12/15LOX augments the biosynthesis of proresolving lipids acutely and chronically after MI, and thereby facilitates LV healing and repair. Collectively, the proposed studies will define the role of 12/15LOX in the initiation, resolution, and progression of inflammation post-MI. To accomplish this, we have enlisted inflammation, HF, and biostatistics experts to complement our expertise in lipid signaling. The new knowledge gained will advance the development of novel therapeutic targets/drugs to ameliorate HF.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = -$210,828 )
2024	2022	UNIVERSITY OF SOUTH FLORIDA	4202 E FOWLER AVE	TAMPA	FL	33620	HILLSBOROUGH	USA	Cardiovascular Diseases Research	000	4	8/29/2024	NON-COMPETING CONTINUATION	-$210,828
														Subtotal = -$210,828

Issue Date FY: 2022 ( Subtotal = $373,750 )
2022	2022	UNIVERSITY OF SOUTH FLORIDA	4202 E FOWLER AVE	TAMPA	FL	33620	HILLSBOROUGH	USA	Cardiovascular Diseases Research	000	4	5/20/2022	NON-COMPETING CONTINUATION	$373,750
														Subtotal = $373,750

Issue Date FY: 2021 ( Subtotal = $373,750 )
2021	2021	UNIVERSITY OF SOUTH FLORIDA	4202 E FOWLER AVE	TAMPA	FL	33620	HILLSBOROUGH	USA	Cardiovascular Diseases Research	000	3	5/24/2021	NON-COMPETING CONTINUATION	$373,750
2021	2020	UNIVERSITY OF SOUTH FLORIDA	4202 E FOWLER AVE	TAMPA	FL	33620	HILLSBOROUGH	USA	Cardiovascular Diseases Research	002	2	5/25/2021	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$210,746
2021	2019	UNIVERSITY OF ALABAMA AT BIRMINGHAM	701 S 20TH ST	BIRMINGHAM	AL	35294	JEFFERSON	USA	Cardiovascular Diseases Research	001	1	5/25/2021	NEW	-$210,746
														Subtotal = $373,750

Issue Date FY: 2020 ( Subtotal = $373,750 )
2020	2020	UNIVERSITY OF SOUTH FLORIDA	4202 E FOWLER AVE	TAMPA	FL	33620	HILLSBOROUGH	USA	Cardiovascular Diseases Research	001	2	8/14/2020	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$373,750
2020	2019	UNIVERSITY OF ALABAMA AT BIRMINGHAM	701 S 20TH ST	BIRMINGHAM	AL	35294	JEFFERSON	USA	Cardiovascular Diseases Research	000	1	8/12/2020	NEW	$0
														Subtotal = $373,750

Issue Date FY: 2019 ( Subtotal = $371,250 )
2019	2019	UNIVERSITY OF ALABAMA AT BIRMINGHAM	701 S 20TH ST	BIRMINGHAM	AL	35294	JEFFERSON	USA	Cardiovascular Diseases Research	000	1	7/17/2019	NEW	$371,250
														Subtotal = $371,250

Grand Total All Awards = $1,281,672

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Lipoxygenase Signaling in Heart Failure Pathology

Award Number: R01HL144788

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/01/2019

PERIOD OF PERFORMANCE END DATE: 05/31/2024

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer